Home › Companies › RHYTHM PHARMACEUTICALS INC. › 2024-2025
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and RHYTHM PHARMACEUTICALS INC.’s Form 8-K, filed June 26, 2025 (Item 5.07 on EDGAR). Page generated November 20, 2026.
Meeting of June 24, 2025: 6 items on RHYTHM PHARMACEUTICALS INC.’s Form 8-K, filed June 26, 2025: 1 approved · 5 passed (calculated).
Meeting of September 18, 2024: 6 items on RHYTHM PHARMACEUTICALS INC.’s Form 8-K, filed September 19, 2024: 1 approved · 5 passed (calculated).
Significant dissent: 1 director (40.3% against); 1 say-on-pay vote (69.4% support); 1 equity or compensation plan (37.2% against).
Notable dissent: 3 directors (13.6%, 12.7%, 12.5% against).
Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided
Proxy season: 2023-2024 2024-2025 2025-2026
Activist investors: Ra Capital Management, L.P. (13F, 9.6%, as of September 30, 2026)
Explore RHYTHM PHARMACEUTICALS INC. in the interactive database Compare manager voting policies
These tallies are RHYTHM PHARMACEUTICALS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 26, 2025 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX. RHYTHM PHARMACEUTICALS INC. reported 2 meetings in this season; each is tabulated separately below, with its own filing.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Jennifer Good | 55,565,432 | -- | -- | 3,393,257 | 1,759,938 | 94% | Passed (calculated) | — |
| Elect Director: Edward T. Mathers | 35,169,176 | -- | -- | 23,789,513 | 1,759,938 | 60% | Passed (calculated) | — |
| 2. Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the year ending December 31, 2025 | 60,554,577 | 158,123 | 5,927 | -- | 0 | 99.7% | Passed (calculated) | — |
| 3. Approval, on an advisory (non-binding) basis, of the compensation of the Company's named executive officers | 40,890,846 | 18,057,763 | 10,080 | -- | 1,759,938 | 69% | Passed (calculated) | — |
| 4. Approval of an amendment to our Amended and Restated Certificate of Incorporation to provide for exculpation of officers from breaches of fiduciary duty to the fullest extent permitted by the General Corporation Law of the State of Delaware (the "Officer Ex | 55,466,440 | 3,483,935 | 8,314 | -- | 1,759,938 | 94% | Passed (calculated) | — |
| 5. Approval of an adjournment of the Annual Meeting, if necessary, to solicit additional proxies if there are not sufficient votes at the time of the Annual Meeting to approve the Officer Exculpation Amendment | 52,278,219 | 6,673,470 | 7,000 | -- | 1,759,938 | 89% | Approved | — |
Source: RHYTHM PHARMACEUTICALS INC., Form 8-K, filed with the SEC on June 26, 2025 — read the filing on EDGAR.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Stuart A. Arbuckle | 45,585,464 | -- | -- | 6,530,701 | 1,829,832 | 87% | Passed (calculated) | — |
| Elect Director: Christophe R. Jean | 45,017,705 | -- | -- | 7,098,460 | 1,829,832 | 86% | Passed (calculated) | — |
| Elect Director: Lynn A. Tetrault | 45,485,067 | -- | -- | 6,631,098 | 1,829,832 | 87% | Passed (calculated) | — |
| 2. Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the year ending December 31, 2024 | 53,844,430 | 69,539 | 32,028 | -- | 0 | 99.9% | Passed (calculated) | — |
| 3. Approval, on an advisory (non-binding) basis, of the compensation of the Company's named executive officers | 50,612,289 | 1,487,317 | 16,559 | -- | 1,829,832 | 97% | Passed (calculated) | — |
| 4. Reapproval of the Rhythm Pharmaceuticals, Inc. 2017 Equity Incentive Plan | 32,739,796 | 19,359,379 | 16,990 | -- | 1,829,832 | 63% | Approved | — |
Source: RHYTHM PHARMACEUTICALS INC., Form 8-K, filed with the SEC on September 19, 2024 — read the filing on EDGAR.
See voting trends for Health Care companies, 2024-2025: shareholder support by sector and by company size.
292 asset managers disclosed a vote on at least one RHYTHM PHARMACEUTICALS INC. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.
Meeting held June 24, 2025.
Combines 4 wordings of this item as funds reported it.
60% Majority: yes · of votes cast
Description as filed by funds: Election of the Class II directors, each to serve for a three year term until the 2028 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified: Edward T. Mathers
RHYTHM PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Edward T. Mathers”): 35,169,176 for, 23,789,513 withheld, per its Form 8-K filed June 26, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 60% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 85 asset managers below reported 11,081,067 for, 7,846,061 withheld, 4,351,574 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| PRIMECAP Odyssey Funds | 5,361,309 | 0 | 0 | 0 | For |
| Vanguard | 3,354,950 | 0 | 0 | 0 | For |
| BlackRock | 0 | 0 | 3,259,015 | 0 | Abstain |
| Fidelity | 0 | 0 | 0 | 2,927,727 | Withhold |
| Federated Hermes | 1,655,570 | 0 | 0 | 0 | For |
| T. Rowe Price | 0 | 0 | 0 | 890,762 | Withhold |
| State Street | 2,028 | 0 | 0 | 716,484 | Withhold |
| ACAP Strategic Fund | 0 | 0 | 0 | 502,832 | Withhold |
| Charles Schwab | 0 | 0 | 0 | 454,523 | Withhold |
| Manager Directed Portfolios | 369,024 | 0 | 0 | 0 | For |
| Putnam | 0 | 0 | 0 | 361,067 | Withhold |
| Loomis Sayles | 0 | 0 | 342,725 | 0 | Abstain |
| HARBOR FUNDS | 0 | 0 | 314,951 | 0 | Abstain |
| JANUS INVESTMENT FUND | 255,643 | 0 | 0 | 0 | For |
| DRIEHAUS MUTUAL FUNDS | 0 | 0 | 0 | 248,237 | Withhold |
| Equitable | 0 | 0 | 0 | 171,898 | Withhold |
| Invesco | 0 | 0 | 0 | 162,016 | Withhold |
| JPMorgan | 0 | 0 | 159,001 | 0 | Abstain |
| Advantage Advisers Xanthus Fund, L.L.C. | 0 | 0 | 0 | 146,151 | Withhold |
| TIAA | 0 | 0 | 0 | 140,826 | Withhold |
| Brighthouse | 0 | 0 | 0 | 112,023 | Withhold |
| QUANTITATIVE MASTER SERIES LLC | 0 | 0 | 94,179 | 0 | Abstain |
| Aberdeen | 0 | 0 | 0 | 79,956 | Withhold |
| First Trust | 0 | 0 | 0 | 74,297 | Withhold |
| Russell Investments | 0 | 0 | 0 | 57,173 | Withhold |
Showing the 25 largest of 85 asset managers. All 85 are in the interactive database (link above).
Meeting held June 24, 2025.
Combines 4 wordings of this item as funds reported it.
94% Majority: yes · of votes cast
Description as filed by funds: Election of the Class II directors, each to serve for a three year term until the 2028 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified: Jennifer Good
RHYTHM PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Jennifer Good”): 55,565,432 for, 3,393,257 withheld, per its Form 8-K filed June 26, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 94% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 85 asset managers below reported 21,444,292 for, 1,115,265 withheld, 719,145 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| PRIMECAP Odyssey Funds | 5,361,309 | 0 | 0 | 0 | For |
| Vanguard | 3,354,950 | 0 | 0 | 0 | For |
| BlackRock | 3,259,015 | 0 | 0 | 0 | For |
| Fidelity | 2,927,727 | 0 | 0 | 0 | For |
| Federated Hermes | 1,655,570 | 0 | 0 | 0 | For |
| T. Rowe Price | 890,762 | 0 | 0 | 0 | For |
| State Street | 718,512 | 0 | 0 | 0 | For |
| ACAP Strategic Fund | 502,832 | 0 | 0 | 0 | For |
| Charles Schwab | 0 | 0 | 0 | 454,523 | Withhold |
| Manager Directed Portfolios | 0 | 0 | 369,024 | 0 | Abstain |
| Putnam | 0 | 0 | 0 | 361,067 | Withhold |
| Loomis Sayles | 0 | 0 | 342,725 | 0 | Abstain |
| HARBOR FUNDS | 314,951 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 255,643 | 0 | 0 | 0 | For |
| DRIEHAUS MUTUAL FUNDS | 248,237 | 0 | 0 | 0 | For |
| Equitable | 111,628 | 0 | 0 | 60,270 | Mixed |
| Invesco | 162,016 | 0 | 0 | 0 | For |
| JPMorgan | 159,001 | 0 | 0 | 0 | For |
| Advantage Advisers Xanthus Fund, L.L.C. | 146,151 | 0 | 0 | 0 | For |
| TIAA | 140,826 | 0 | 0 | 0 | For |
| Brighthouse | 47,803 | 0 | 0 | 64,220 | Mixed |
| QUANTITATIVE MASTER SERIES LLC | 94,179 | 0 | 0 | 0 | For |
| Aberdeen | 79,956 | 0 | 0 | 0 | For |
| First Trust | 74,297 | 0 | 0 | 0 | For |
| Russell Investments | 0 | 0 | 0 | 57,173 | Withhold |
Showing the 25 largest of 85 asset managers. All 85 are in the interactive database (link above).
Meeting held September 18, 2024.
Combines 4 wordings of this item as funds reported it.
86% Majority: yes · of votes cast
Description as filed by funds: Election of the Class I directors, each to serve for a three year term until the 2027 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified: Christophe R. Jean
RHYTHM PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Christophe R. Jean”): 45,017,705 for, 7,098,460 withheld, per its Form 8-K filed September 19, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts using a plurality of the votes cast, the standard stated in the company’s proxy statement: votes for exceeded votes against.
Support: 86% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 75 asset managers below reported 19,663,318 for, 1,619,286 withheld, 47,993 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| PRIMECAP Odyssey Funds | 6,960,312 | 0 | 0 | 0 | For |
| BlackRock | 3,355,396 | 0 | 0 | 0 | For |
| Vanguard | 3,217,318 | 0 | 0 | 0 | For |
| Federated Hermes | 1,660,780 | 0 | 0 | 0 | For |
| Fidelity | 1,111,550 | 0 | 0 | 8,627 | For |
| State Street | 656,003 | 0 | 0 | 794 | For |
| ACAP Strategic Fund | 0 | 0 | 0 | 490,138 | Withhold |
| Charles Schwab | 430,047 | 0 | 0 | 0 | For |
| T. Rowe Price | 392,639 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 287,724 | 0 | 0 | 0 | For |
| Loomis Sayles | 245,281 | 0 | 0 | 0 | For |
| Putnam | 0 | 0 | 0 | 215,035 | Withhold |
| Manager Directed Portfolios | 207,361 | 0 | 0 | 0 | For |
| Artisan | 171,239 | 0 | 0 | 0 | For |
| Invesco | 167,600 | 0 | 0 | 0 | For |
| Equitable | 105,647 | 0 | 0 | 59,570 | Mixed |
| DRIEHAUS MUTUAL FUNDS | 0 | 0 | 0 | 158,419 | Withhold |
| TIAA | 146,270 | 0 | 0 | 0 | For |
| Advantage Advisers Xanthus Fund, L.L.C. | 0 | 0 | 0 | 146,200 | Withhold |
| Aberdeen | 0 | 0 | 0 | 112,804 | Withhold |
| Brighthouse | 76,856 | 0 | 0 | 13,635 | Mixed |
| First Trust | 0 | 0 | 0 | 70,091 | Withhold |
| Legg Mason | 59,600 | 0 | 0 | 4,471 | Mixed |
| QUANTITATIVE MASTER SERIES LLC | 61,324 | 0 | 0 | 0 | For |
| RBB FUND, INC. | 0 | 0 | 0 | 57,988 | Withhold |
Showing the 25 largest of 75 asset managers. All 75 are in the interactive database (link above).
Meeting held September 18, 2024.
Combines 4 wordings of this item as funds reported it.
87% Majority: yes · of votes cast
Description as filed by funds: Election of the Class I directors, each to serve for a three year term until the 2027 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified: Lynn A. Tetrault
RHYTHM PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Lynn A. Tetrault”): 45,485,067 for, 6,631,098 withheld, per its Form 8-K filed September 19, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts using a plurality of the votes cast, the standard stated in the company’s proxy statement: votes for exceeded votes against.
Support: 87% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 75 asset managers below reported 19,701,291 for, 1,579,736 withheld, 49,570 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| PRIMECAP Odyssey Funds | 6,960,312 | 0 | 0 | 0 | For |
| BlackRock | 3,355,396 | 0 | 0 | 0 | For |
| Vanguard | 3,217,318 | 0 | 0 | 0 | For |
| Federated Hermes | 1,660,780 | 0 | 0 | 0 | For |
| Fidelity | 1,111,550 | 0 | 0 | 8,627 | For |
| State Street | 656,003 | 0 | 0 | 794 | For |
| ACAP Strategic Fund | 0 | 0 | 0 | 490,138 | Withhold |
| Charles Schwab | 430,047 | 0 | 0 | 0 | For |
| T. Rowe Price | 392,639 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 287,724 | 0 | 0 | 0 | For |
| Loomis Sayles | 245,281 | 0 | 0 | 0 | For |
| Putnam | 0 | 0 | 0 | 215,035 | Withhold |
| Manager Directed Portfolios | 207,361 | 0 | 0 | 0 | For |
| Artisan | 171,239 | 0 | 0 | 0 | For |
| Invesco | 167,600 | 0 | 0 | 0 | For |
| Equitable | 105,647 | 0 | 0 | 59,570 | Mixed |
| DRIEHAUS MUTUAL FUNDS | 0 | 0 | 0 | 158,419 | Withhold |
| TIAA | 146,270 | 0 | 0 | 0 | For |
| Advantage Advisers Xanthus Fund, L.L.C. | 0 | 0 | 0 | 146,200 | Withhold |
| Aberdeen | 0 | 0 | 0 | 112,804 | Withhold |
| Brighthouse | 76,856 | 0 | 0 | 13,635 | Mixed |
| First Trust | 0 | 0 | 0 | 70,091 | Withhold |
| Legg Mason | 59,600 | 0 | 0 | 4,471 | Mixed |
| QUANTITATIVE MASTER SERIES LLC | 61,324 | 0 | 0 | 0 | For |
| RBB FUND, INC. | 0 | 0 | 0 | 57,988 | Withhold |
Showing the 25 largest of 75 asset managers. All 75 are in the interactive database (link above).
Meeting held September 18, 2024.
Combines 4 wordings of this item as funds reported it.
87% Majority: yes · of votes cast
Description as filed by funds: Election of the Class I directors, each to serve for a three year term until the 2027 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified: Stuart A. Arbuckle
RHYTHM PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Stuart A. Arbuckle”): 45,585,464 for, 6,530,701 withheld, per its Form 8-K filed September 19, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts using a plurality of the votes cast, the standard stated in the company’s proxy statement: votes for exceeded votes against.
Support: 87% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 75 asset managers below reported 19,702,868 for, 1,579,736 withheld, 47,993 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| PRIMECAP Odyssey Funds | 6,960,312 | 0 | 0 | 0 | For |
| BlackRock | 3,355,396 | 0 | 0 | 0 | For |
| Vanguard | 3,217,318 | 0 | 0 | 0 | For |
| Federated Hermes | 1,660,780 | 0 | 0 | 0 | For |
| Fidelity | 1,111,550 | 0 | 0 | 8,627 | For |
| State Street | 656,003 | 0 | 0 | 794 | For |
| ACAP Strategic Fund | 0 | 0 | 0 | 490,138 | Withhold |
| Charles Schwab | 430,047 | 0 | 0 | 0 | For |
| T. Rowe Price | 392,639 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 287,724 | 0 | 0 | 0 | For |
| Loomis Sayles | 245,281 | 0 | 0 | 0 | For |
| Putnam | 0 | 0 | 0 | 215,035 | Withhold |
| Manager Directed Portfolios | 207,361 | 0 | 0 | 0 | For |
| Artisan | 171,239 | 0 | 0 | 0 | For |
| Invesco | 167,600 | 0 | 0 | 0 | For |
| Equitable | 105,647 | 0 | 0 | 59,570 | Mixed |
| DRIEHAUS MUTUAL FUNDS | 0 | 0 | 0 | 158,419 | Withhold |
| TIAA | 146,270 | 0 | 0 | 0 | For |
| Advantage Advisers Xanthus Fund, L.L.C. | 0 | 0 | 0 | 146,200 | Withhold |
| Aberdeen | 0 | 0 | 0 | 112,804 | Withhold |
| Brighthouse | 76,856 | 0 | 0 | 13,635 | Mixed |
| First Trust | 0 | 0 | 0 | 70,091 | Withhold |
| Legg Mason | 59,600 | 0 | 0 | 4,471 | Mixed |
| QUANTITATIVE MASTER SERIES LLC | 61,324 | 0 | 0 | 0 | For |
| RBB FUND, INC. | 0 | 0 | 0 | 57,988 | Withhold |
Showing the 25 largest of 75 asset managers. All 75 are in the interactive database (link above).
Meeting held June 24, 2025.
Combines 4 wordings of this item as funds reported it.
94% Majority: yes · of votes cast
Description as filed by funds: Approval of an amendment to our Amended and Restated Certificate of Incorporation to provide for exculpation of officers from breaches of fiduciary duty to the fullest extent permitted by the General Corporation Law of the State of Delaware (the "Officer Exculpation Proposal").
RHYTHM PHARMACEUTICALS INC.’s own tally for this item (“4. Approval of an amendment to our Amended and Restated Certificate of Incorporation to provide for exculpation of officers from breaches of fiduciary duty to the fullest extent permitted by the General Corporation Law o”): 55,466,440 for, 3,483,935 against, per its Form 8-K filed June 26, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 94% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 85 asset managers below reported 22,169,435 for, 1,104,496 against, 4,771 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| PRIMECAP Odyssey Funds | 5,361,309 | 0 | 0 | 0 | For |
| Vanguard | 3,354,950 | 0 | 0 | 0 | For |
| BlackRock | 3,259,015 | 0 | 0 | 0 | For |
| Fidelity | 2,927,727 | 0 | 0 | 0 | For |
| Federated Hermes | 1,655,570 | 0 | 0 | 0 | For |
| T. Rowe Price | 890,762 | 0 | 0 | 0 | For |
| State Street | 718,079 | 433 | 0 | 0 | For |
| ACAP Strategic Fund | 502,832 | 0 | 0 | 0 | For |
| Charles Schwab | 454,523 | 0 | 0 | 0 | For |
| Manager Directed Portfolios | 0 | 369,024 | 0 | 0 | Against |
| Putnam | 361,067 | 0 | 0 | 0 | For |
| Loomis Sayles | 0 | 342,725 | 0 | 0 | Against |
| HARBOR FUNDS | 314,951 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 255,643 | 0 | 0 | 0 | For |
| DRIEHAUS MUTUAL FUNDS | 248,237 | 0 | 0 | 0 | For |
| Equitable | 171,898 | 0 | 0 | 0 | For |
| Invesco | 162,016 | 0 | 0 | 0 | For |
| JPMorgan | 0 | 159,001 | 0 | 0 | Against |
| Advantage Advisers Xanthus Fund, L.L.C. | 146,151 | 0 | 0 | 0 | For |
| TIAA | 140,826 | 0 | 0 | 0 | For |
| Brighthouse | 47,803 | 64,220 | 0 | 0 | Mixed |
| QUANTITATIVE MASTER SERIES LLC | 94,179 | 0 | 0 | 0 | For |
| Aberdeen | 79,956 | 0 | 0 | 0 | For |
| First Trust | 74,297 | 0 | 0 | 0 | For |
| Russell Investments | 0 | 57,173 | 0 | 0 | Against |
Showing the 25 largest of 85 asset managers. All 85 are in the interactive database (link above).
Meeting held June 24, 2025.
89% Approved · of votes cast
Description as filed by funds: APPROVAL OF AN ADJOURNMENT OF THE ANNUAL MEETING, IF NECESSARY, TO SOLICIT ADDITIONAL PROXIES IF THERE ARE NOT SUFFICIENT VOTES AT THE TIME OF THE ANNUAL MEETING TO APPROVE THE OFFICER EXCULPATION AMENDMENT.
RHYTHM PHARMACEUTICALS INC.’s own tally for this item (“5. Approval of an adjournment of the Annual Meeting, if necessary, to solicit additional proxies if there are not sufficient votes at the time of the Annual Meeting to approve the Officer Exculpation Amendment”): 52,278,219 for, 6,673,470 against — passed, per its Form 8-K filed June 26, 2025 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal 5: Approval of an adjournment of the Annual Meeting, if necessary, to solicit additional proxies if there are not sufficient votes at the time of the Annual Meeting to approve the Officer Exculpation Amendment”
Support: 89% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 83 asset managers below reported 20,150,059 for, 3,121,568 against, 4,771 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| PRIMECAP Odyssey Funds | 5,361,309 | 0 | 0 | 0 | For |
| Vanguard | 3,354,950 | 0 | 0 | 0 | For |
| BlackRock | 3,259,015 | 0 | 0 | 0 | For |
| Fidelity | 2,927,727 | 0 | 0 | 0 | For |
| Federated Hermes | 1,655,570 | 0 | 0 | 0 | For |
| T. Rowe Price | 0 | 890,762 | 0 | 0 | Against |
| State Street | 12,327 | 706,185 | 0 | 0 | Against |
| ACAP Strategic Fund | 502,832 | 0 | 0 | 0 | For |
| Charles Schwab | 0 | 454,523 | 0 | 0 | Against |
| Manager Directed Portfolios | 0 | 369,024 | 0 | 0 | Against |
| Putnam | 361,067 | 0 | 0 | 0 | For |
| Loomis Sayles | 0 | 342,725 | 0 | 0 | Against |
| HARBOR FUNDS | 314,951 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 255,643 | 0 | 0 | 0 | For |
| DRIEHAUS MUTUAL FUNDS | 248,237 | 0 | 0 | 0 | For |
| Equitable | 167,020 | 4,878 | 0 | 0 | For |
| Invesco | 162,016 | 0 | 0 | 0 | For |
| JPMorgan | 159,001 | 0 | 0 | 0 | For |
| Advantage Advisers Xanthus Fund, L.L.C. | 146,151 | 0 | 0 | 0 | For |
| TIAA | 140,826 | 0 | 0 | 0 | For |
| Brighthouse | 19,681 | 92,342 | 0 | 0 | Mixed |
| QUANTITATIVE MASTER SERIES LLC | 94,179 | 0 | 0 | 0 | For |
| Aberdeen | 79,956 | 0 | 0 | 0 | For |
| First Trust | 74,297 | 0 | 0 | 0 | For |
| Russell Investments | 0 | 57,173 | 0 | 0 | Against |
Showing the 25 largest of 83 asset managers. All 83 are in the interactive database (link above).
Meeting held September 18, 2024.
Combines 2 wordings of this item as funds reported it.
63% Approved · of votes cast
Description as filed by funds: Reapproval of the Rhythm Pharmaceuticals, Inc. 2017 Equity Incentive Plan.
RHYTHM PHARMACEUTICALS INC.’s own tally for this item (“4. Reapproval of the Rhythm Pharmaceuticals, Inc. 2017 Equity Incentive Plan”): 32,739,796 for, 19,359,379 against — passed, per its Form 8-K filed September 19, 2024 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Item 4 - Reapproval of the Rhythm Pharmaceuticals, Inc. 2017 Equity Incentive Plan.”
Support: 63% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| PRIMECAP Odyssey Funds | 6,960,312 | 0 | 0 | 0 | For |
| BlackRock | 0 | 3,355,396 | 0 | 0 | Against |
| Vanguard | 3,217,318 | 0 | 0 | 0 | For |
| Federated Hermes | 1,660,780 | 0 | 0 | 0 | For |
| Fidelity | 0 | 1,120,177 | 0 | 0 | Against |
| State Street | 644 | 656,153 | 0 | 0 | Against |
| ACAP Strategic Fund | 0 | 490,138 | 0 | 0 | Against |
| Charles Schwab | 0 | 430,047 | 0 | 0 | Against |
| T. Rowe Price | 0 | 392,639 | 0 | 0 | Against |
| JANUS INVESTMENT FUND | 287,724 | 0 | 0 | 0 | For |
| Loomis Sayles | 0 | 245,281 | 0 | 0 | Against |
| Putnam | 0 | 215,035 | 0 | 0 | Against |
| Manager Directed Portfolios | 0 | 207,361 | 0 | 0 | Against |
| Artisan | 0 | 171,239 | 0 | 0 | Against |
| Invesco | 0 | 167,600 | 0 | 0 | Against |
| Equitable | 10,882 | 154,335 | 0 | 0 | Mixed |
| DRIEHAUS MUTUAL FUNDS | 0 | 158,419 | 0 | 0 | Against |
| TIAA | 0 | 146,270 | 0 | 0 | Against |
| Advantage Advisers Xanthus Fund, L.L.C. | 0 | 146,200 | 0 | 0 | Against |
| Aberdeen | 0 | 112,804 | 0 | 0 | Against |
| Brighthouse | 0 | 90,491 | 0 | 0 | Against |
| First Trust | 0 | 70,091 | 0 | 0 | Against |
| Legg Mason | 0 | 64,071 | 0 | 0 | Against |
| QUANTITATIVE MASTER SERIES LLC | 0 | 61,324 | 0 | 0 | Against |
| RBB FUND, INC. | 0 | 57,988 | 0 | 0 | Against |
Fund voting reports, all 74 managers: 12,203,550 for, 9,117,845 against, 8,457 abstained. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| NEA Management Company, LLC | 2,909,956 | 0 | 0 | 0 | For |
| ALGERT GLOBAL LLC | 0 | 58,919 | 0 | 0 | Against |
| UNITED CAPITAL FINANCIAL ADVISORS, LLC | 0 | 147 | 0 | 0 | Against |
Institutional-manager reports, all 3 managers: 2,909,956 for, 59,066 against.
Meeting held June 24, 2025.
Combines 8 wordings of this item as funds reported it.
69% Majority: yes · of votes cast
Description as filed by funds: Approval, on an advisory (non- binding) basis, of the compensation of the named executive officers of the Company.
RHYTHM PHARMACEUTICALS INC.’s own tally for this item (“3. Approval, on an advisory (non-binding) basis, of the compensation of the Company's named executive officers”): 40,890,846 for, 18,057,763 against, per its Form 8-K filed June 26, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 69% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| PRIMECAP Odyssey Funds | 5,361,309 | 0 | 0 | 0 | For |
| Vanguard | 3,354,950 | 0 | 0 | 0 | For |
| BlackRock | 0 | 3,259,015 | 0 | 0 | Against |
| Fidelity | 1,753,300 | 1,174,427 | 0 | 0 | Mixed |
| Federated Hermes | 1,655,570 | 0 | 0 | 0 | For |
| T. Rowe Price | 883,462 | 0 | 0 | 0 | For |
| State Street | 708,171 | 10,341 | 0 | 0 | For |
| ACAP Strategic Fund | 0 | 502,832 | 0 | 0 | Against |
| Charles Schwab | 0 | 454,523 | 0 | 0 | Against |
| Manager Directed Portfolios | 0 | 369,024 | 0 | 0 | Against |
| Putnam | 0 | 361,067 | 0 | 0 | Against |
| Loomis Sayles | 0 | 342,725 | 0 | 0 | Against |
| HARBOR FUNDS | 0 | 314,951 | 0 | 0 | Against |
| JANUS INVESTMENT FUND | 255,643 | 0 | 0 | 0 | For |
| DRIEHAUS MUTUAL FUNDS | 248,237 | 0 | 0 | 0 | For |
| Equitable | 24,326 | 147,572 | 0 | 0 | Mixed |
| Invesco | 0 | 162,016 | 0 | 0 | Against |
| JPMorgan | 159,001 | 0 | 0 | 0 | For |
| Advantage Advisers Xanthus Fund, L.L.C. | 0 | 146,151 | 0 | 0 | Against |
| TIAA | 115,412 | 0 | 0 | 0 | For |
| Brighthouse | 28,122 | 83,901 | 0 | 0 | Mixed |
| QUANTITATIVE MASTER SERIES LLC | 0 | 94,179 | 0 | 0 | Against |
| Aberdeen | 79,956 | 0 | 0 | 0 | For |
| First Trust | 0 | 74,297 | 0 | 0 | Against |
| Russell Investments | 0 | 57,173 | 0 | 0 | Against |
Fund voting reports, all 84 managers: 15,108,156 for, 8,131,502 against, 4,771 abstained. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| PRIMECAP MANAGEMENT CO/CA/ | 5,636,697 | 0 | 0 | 0 | For |
| BAKER BROS. ADVISORS LP | 5,604,483 | 0 | 0 | 0 | For |
| RA CAPITAL MANAGEMENT, L.P. | 5,491,123 | 0 | 0 | 0 | For |
| NEA Management Company, LLC | 2,911,349 | 0 | 0 | 0 | For |
| BlackRock | 27,688 | 2,708,049 | 0 | 0 | Against |
| PERCEPTIVE ADVISORS LLC | 1,990,967 | 0 | 0 | 0 | For |
| Fidelity | 1,811,271 | 0 | 0 | 0 | For |
| State Street | 1,750,633 | 25,781 | 0 | 0 | For |
| Federated Hermes | 1,659,737 | 0 | 0 | 0 | For |
| Janus Henderson | 1,580,939 | 36,718 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 0 | 1,299,568 | 0 | 0 | Against |
| T. Rowe Price | 1,228,245 | 0 | 0 | 0 | For |
| WESTFIELD CAPITAL MANAGEMENT CO LP | 0 | 1,101,032 | 0 | 0 | Against |
| Checkpoint Capital L.P. | 1,043,775 | 0 | 0 | 0 | For |
| DRIEHAUS CAPITAL MANAGEMENT LLC | 839,732 | 0 | 0 | 0 | For |
| Hood River Capital Management LLC | 0 | 649,160 | 0 | 0 | Against |
| MARSHALL WACE, LLP | 0 | 633,696 | 0 | 0 | Against |
| Loomis Sayles | 0 | 586,960 | 0 | 0 | Against |
| Putnam | 0 | 479,059 | 0 | 0 | Against |
| Opaleye Management Inc. | 475,000 | 0 | 0 | 0 | For |
| Northern Trust | 446,709 | 12,450 | 0 | 0 | For |
| Charles Schwab | 0 | 454,692 | 0 | 0 | Against |
| Point72 | 0 | 331,189 | 0 | 0 | Against |
| PICTET ASSET MANAGEMENT SA | 0 | 326,948 | 0 | 0 | Against |
| Rock Springs Capital Management LP | 312,096 | 0 | 0 | 0 | For |
Institutional-manager reports, all 203 managers: 34,379,582 for, 11,588,006 against, 891 abstained, 252 not voted. Showing the 25 largest; every one is in the interactive database (link above).
Meeting held September 18, 2024.
Combines 7 wordings of this item as funds reported it.
97% Majority: yes · of votes cast
Description as filed by funds: APPROVAL, ON AN ADVISORY (NON-BINDING) BASIS, OF THE COMPENSATION OF THE NAMED EXECUTIVE OFFICERS OF THE COMPANY.
RHYTHM PHARMACEUTICALS INC.’s own tally for this item (“3. Approval, on an advisory (non-binding) basis, of the compensation of the Company's named executive officers”): 50,612,289 for, 1,487,317 against, per its Form 8-K filed September 19, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 97% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| PRIMECAP Odyssey Funds | 6,960,312 | 0 | 0 | 0 | For |
| BlackRock | 3,355,396 | 0 | 0 | 0 | For |
| Vanguard | 3,217,318 | 0 | 0 | 0 | For |
| Federated Hermes | 1,660,780 | 0 | 0 | 0 | For |
| Fidelity | 1,120,177 | 0 | 0 | 0 | For |
| State Street | 656,797 | 0 | 0 | 0 | For |
| ACAP Strategic Fund | 490,138 | 0 | 0 | 0 | For |
| Charles Schwab | 430,047 | 0 | 0 | 0 | For |
| T. Rowe Price | 392,639 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 287,724 | 0 | 0 | 0 | For |
| Loomis Sayles | 245,281 | 0 | 0 | 0 | For |
| Putnam | 215,035 | 0 | 0 | 0 | For |
| Manager Directed Portfolios | 207,361 | 0 | 0 | 0 | For |
| Artisan | 171,239 | 0 | 0 | 0 | For |
| Invesco | 0 | 167,600 | 0 | 0 | Against |
| Equitable | 165,217 | 0 | 0 | 0 | For |
| DRIEHAUS MUTUAL FUNDS | 158,419 | 0 | 0 | 0 | For |
| Advantage Advisers Xanthus Fund, L.L.C. | 146,200 | 0 | 0 | 0 | For |
| Aberdeen | 112,804 | 0 | 0 | 0 | For |
| TIAA | 99,727 | 0 | 0 | 0 | For |
| Brighthouse | 90,491 | 0 | 0 | 0 | For |
| First Trust | 70,091 | 0 | 0 | 0 | For |
| Legg Mason | 64,071 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 61,324 | 0 | 0 | 0 | For |
| RBB FUND, INC. | 57,988 | 0 | 0 | 0 | For |
Fund voting reports, all 74 managers: 21,078,387 for, 195,821 against, 8,457 abstained. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| PRIMECAP MANAGEMENT CO/CA/ | 7,305,791 | 0 | 0 | 0 | For |
| BAKER BROS. ADVISORS LP | 6,398,365 | 0 | 0 | 0 | For |
| RA CAPITAL MANAGEMENT, L.P. | 3,944,490 | 0 | 0 | 0 | For |
| NEA Management Company, LLC | 2,909,956 | 0 | 0 | 0 | For |
| Frazier Life Sciences Management, L.P. | 2,416,952 | 0 | 0 | 0 | For |
| PERCEPTIVE ADVISORS LLC | 2,107,681 | 0 | 0 | 0 | For |
| BlackRock | 1,741,149 | 0 | 0 | 0 | For |
| State Street | 1,714,584 | 0 | 0 | 0 | For |
| Federated Hermes | 1,660,782 | 0 | 0 | 0 | For |
| Rock Springs Capital Management LP | 1,235,490 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 1,160,755 | 0 | 0 | 0 | For |
| DRIEHAUS CAPITAL MANAGEMENT LLC | 754,322 | 0 | 0 | 0 | For |
| ORBIMED ADVISORS LLC | 704,842 | 0 | 0 | 0 | For |
| Commodore Capital LP | 700,000 | 0 | 0 | 0 | For |
| Checkpoint Capital L.P. | 616,715 | 0 | 0 | 0 | For |
| T. Rowe Price | 543,174 | 0 | 0 | 0 | For |
| PICTET ASSET MANAGEMENT SA | 523,048 | 0 | 0 | 0 | For |
| Opaleye Management Inc. | 505,000 | 0 | 0 | 0 | For |
| Charles Schwab | 430,057 | 0 | 0 | 0 | For |
| Putnam | 428,728 | 0 | 0 | 0 | For |
| Northern Trust | 422,177 | 0 | 0 | 0 | For |
| CANADA PENSION PLAN INVESTMENT BOARD | 417,000 | 0 | 0 | 0 | For |
| Loomis Sayles | 415,263 | 0 | 0 | 0 | For |
| Hood River Capital Management LLC | 374,920 | 0 | 0 | 0 | For |
| Janus Henderson | 368,011 | 0 | 0 | 0 | For |
Institutional-manager reports, all 169 managers: 42,689,114 for, 1,112,804 against, 440 abstained, 128 not voted. Showing the 25 largest; every one is in the interactive database (link above).
Meeting held June 24, 2025.
Combines 2 wordings of this item as funds reported it.
99.7% Majority: yes · of votes cast
Description as filed by funds: RATIFICATION OF THE APPOINTMENT OF ERNST & YOUNG LLP AS THE INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE COMPANY FOR THE FISCAL YEAR ENDING DECEMBER 31, 2025.
RHYTHM PHARMACEUTICALS INC.’s own tally for this item (“2. Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the year ending December 31, 2025”): 60,554,577 for, 158,123 against, per its Form 8-K filed June 26, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 99.7% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 85 asset managers below reported 23,243,473 for, 30,458 against, 4,771 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| PRIMECAP Odyssey Funds | 5,361,309 | 0 | 0 | 0 | For |
| Vanguard | 3,354,950 | 0 | 0 | 0 | For |
| BlackRock | 3,259,015 | 0 | 0 | 0 | For |
| Fidelity | 2,927,727 | 0 | 0 | 0 | For |
| Federated Hermes | 1,655,570 | 0 | 0 | 0 | For |
| T. Rowe Price | 890,762 | 0 | 0 | 0 | For |
| State Street | 718,471 | 41 | 0 | 0 | For |
| ACAP Strategic Fund | 502,832 | 0 | 0 | 0 | For |
| Charles Schwab | 454,523 | 0 | 0 | 0 | For |
| Manager Directed Portfolios | 369,024 | 0 | 0 | 0 | For |
| Putnam | 361,067 | 0 | 0 | 0 | For |
| Loomis Sayles | 342,725 | 0 | 0 | 0 | For |
| HARBOR FUNDS | 314,951 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 255,643 | 0 | 0 | 0 | For |
| DRIEHAUS MUTUAL FUNDS | 248,237 | 0 | 0 | 0 | For |
| Equitable | 171,898 | 0 | 0 | 0 | For |
| Invesco | 162,016 | 0 | 0 | 0 | For |
| JPMorgan | 159,001 | 0 | 0 | 0 | For |
| Advantage Advisers Xanthus Fund, L.L.C. | 146,151 | 0 | 0 | 0 | For |
| TIAA | 140,826 | 0 | 0 | 0 | For |
| Brighthouse | 112,023 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 94,179 | 0 | 0 | 0 | For |
| Aberdeen | 79,956 | 0 | 0 | 0 | For |
| First Trust | 74,297 | 0 | 0 | 0 | For |
| Russell Investments | 57,173 | 0 | 0 | 0 | For |
Showing the 25 largest of 85 asset managers. All 85 are in the interactive database (link above).
Meeting held September 18, 2024.
99.9% Majority: yes · of votes cast
Description as filed by funds: Ratification of the appointment of Ernst & Young LLP as the independent registered public accounting firm for the Company for the fiscal year ending December 31, 2024.
RHYTHM PHARMACEUTICALS INC.’s own tally for this item (“2. Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the year ending December 31, 2024”): 53,844,430 for, 69,539 against, per its Form 8-K filed September 19, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 72 asset managers below reported 21,319,701 for, 91 against, 8,457 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| PRIMECAP Odyssey Funds | 6,960,312 | 0 | 0 | 0 | For |
| BlackRock | 3,355,396 | 0 | 0 | 0 | For |
| Vanguard | 3,217,318 | 0 | 0 | 0 | For |
| Federated Hermes | 1,660,780 | 0 | 0 | 0 | For |
| Fidelity | 1,120,177 | 0 | 0 | 0 | For |
| State Street | 656,706 | 91 | 0 | 0 | For |
| ACAP Strategic Fund | 490,138 | 0 | 0 | 0 | For |
| Charles Schwab | 430,047 | 0 | 0 | 0 | For |
| T. Rowe Price | 392,639 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 287,724 | 0 | 0 | 0 | For |
| Loomis Sayles | 245,281 | 0 | 0 | 0 | For |
| Putnam | 215,035 | 0 | 0 | 0 | For |
| Manager Directed Portfolios | 207,361 | 0 | 0 | 0 | For |
| Artisan | 171,239 | 0 | 0 | 0 | For |
| Invesco | 167,600 | 0 | 0 | 0 | For |
| Equitable | 165,217 | 0 | 0 | 0 | For |
| DRIEHAUS MUTUAL FUNDS | 158,419 | 0 | 0 | 0 | For |
| TIAA | 146,270 | 0 | 0 | 0 | For |
| Advantage Advisers Xanthus Fund, L.L.C. | 146,200 | 0 | 0 | 0 | For |
| Aberdeen | 112,804 | 0 | 0 | 0 | For |
| Brighthouse | 90,491 | 0 | 0 | 0 | For |
| First Trust | 70,091 | 0 | 0 | 0 | For |
| Legg Mason | 64,071 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 61,324 | 0 | 0 | 0 | For |
| RBB FUND, INC. | 57,988 | 0 | 0 | 0 | For |
Showing the 25 largest of 72 asset managers. All 72 are in the interactive database (link above).
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 63,494,892 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | PRIMECAP Odyssey Funds | 8.44% |
| 2 | Vanguard | 5.28% |
| 3 | BlackRock | 5.13% |
| 4 | Fidelity | 4.61% |
| 5 | Federated Hermes | 2.61% |
| 6 | T. Rowe Price | 1.39% |
| 7 | State Street | 1.13% |
| 8 | ACAP Strategic Fund | 0.79% |
| 9 | Charles Schwab | 0.72% |
| 10 | Manager Directed Portfolios | 0.58% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | PRIMECAP MANAGEMENT CO/CA/ | 8.88% |
| 2 | BAKER BROS. ADVISORS LP | 8.83% |
| 3 | RA CAPITAL MANAGEMENT, L.P. | 8.65% |
| 4 | NEA Management Company, LLC | 4.59% |
| 5 | BlackRock | 4.31% |
| 6 | PERCEPTIVE ADVISORS LLC | 3.14% |
| 7 | Fidelity | 2.85% |
| 8 | State Street | 2.80% |
| 9 | Federated Hermes | 2.61% |
| 10 | Janus Henderson | 2.55% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.
| Holder | Shares | % outstanding | Source, as of |
|---|---|---|---|
| BlackRock | 6,854,755 | 10.80% | Form 13F, quarter ended March 31, 2025 |
| RA Capital Management, L.P. | 6,666,837 | 10.50% | Schedule 13G, filed February 17, 2026 |
| Baker Bros. Advisors LP | 5,604,483 | 8.83% | Schedule 13G, filed May 15, 2025 |
| Perceptive Advisors LLC | 3,519,626 | 5.54% | Schedule 13G, filed May 15, 2026 |
| PRIMECAP MANAGEMENT CO/CA/ | 3,478,669 | 5.48% | Schedule 13G, filed February 12, 2026 |
| Vanguard Group | 3,444,926 | 5.43% | Form 13F, quarter ended March 31, 2025 |
| State Street | 1,970,733 | 3.10% | Form 13F, quarter ended March 31, 2025 |
| FMR (Fidelity) | 1,688,375 | 2.66% | Form 13F, quarter ended March 31, 2025 |
| Goldman Sachs | 1,637,908 | 2.58% | Form 13F, quarter ended March 31, 2025 |
| T. Rowe Price | 1,199,053 | 1.89% | Form 13F, quarter ended March 31, 2025 |
Percentages above are of 63,494,892 shares outstanding, as reported by RHYTHM PHARMACEUTICALS INC. on its Form 10-Q dated March 31, 2025 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
At RHYTHM PHARMACEUTICALS INC.'s 2 shareholder meetings in the 2024-2025 proxy season (held September 18, 2024 and June 24, 2025), 292 asset managers reported votes on at least one of its 12 ballot items in their SEC Form N-PX filings, covering 3,089 separate fund positions. On the most widely held item of the season, voted at the meeting held June 24, 2025 — Approval, on an advisory (non- binding) basis, of the compensation of the named executive… — FOR was 69% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: RHYTHM PHARMACEUTICALS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 26, 2025.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from RHYTHM PHARMACEUTICALS INC.’s 10-Q dated March 31, 2025. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.
RHYTHM PHARMACEUTICALS INC. proxy season coverage: 2023-2024 · 2024-2025 (this page) · 2025-2026.
Proxy Votes Now, “RHYTHM PHARMACEUTICALS (RYTM) 2024-2025 Annual Meetings: Vote Results”, https://proxyvotesnow.com/company/rhythm-pharmaceuticals-inc/2025 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.